Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vir Biotechnology (VIR)

Vir Biotechnology Q3 net loss narrows to $163.1 million; revenue falls to $0.2 million

Mixed Impact 3 of 5 earnings Written later

Vir Biotechnology reported third quarter 2025 results for the period ended September 30, 2025. Net loss narrowed to $163.1 million, or $1.17 per share, from $213.7 million, or $1.56 per share, a year earlier, mainly because license expenses were lower than in the prior-year quarter, but total revenues fell to $0.2 million from $2.4 million. The company said it had $810.7 million in cash, cash equivalents and investments and expects that to fund operations into mid-2027.

Key points

  • Net loss was $163.1 million, or $1.17 per share, versus $213.7 million, or $1.56 per share, in Q3 2024
  • Total revenues were $0.2 million versus $2.4 million in Q3 2024; R&D expenses were $151.5 million versus $195.2 million
  • Cash, cash equivalents and investments were $810.7 million at September 30, 2025, down about $81.4 million in the quarter; ECLIPSE 1 Phase 3 enrollment completed about two months early

The filing

CompanyVir Biotechnology (VIR)
Form8-K, current report
Filed with the SECNov 5, 2025, 4:12 PM ET
Accession number0001628280-25-049561

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.